<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884169</url>
  </required_header>
  <id_info>
    <org_study_id>M518101-EU03</org_study_id>
    <nct_id>NCT00884169</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study is to investigate the efficacy and safety of M518101 in male and female plaque&#xD;
      psoriasis patients with refractory plaques.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date>December 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of plaque psoriasis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator and Patient overall assessment</measure>
  </secondary_outcome>
  <condition>Plaque Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M518101</intervention_name>
    <description>Proper quantity twice a day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Proper quantity twice a day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Who are able and willing to give signed informed consent&#xD;
&#xD;
          -  Who are male or females aged between 18 and 65 years with plaque psoriasis confirmed&#xD;
             by the Investigator.&#xD;
&#xD;
          -  Who have less than 20% of body surface area (BSA) afflicted with plaques&#xD;
&#xD;
          -  Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Who have a history of allergy to vitamin D3 derivative preparations.&#xD;
&#xD;
          -  Who have a history of relevant drug hypersensitivity.&#xD;
&#xD;
          -  Who have a history of contact dermatitis induced by a topical medicine.&#xD;
&#xD;
          -  Who are pregnant or lactating.&#xD;
&#xD;
          -  Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal&#xD;
             or hepatic disease.&#xD;
&#xD;
          -  Who have clinically relevant history or presence of any disease or surgical history&#xD;
             other than psoriasis which is likely to affect the conduct of the study.&#xD;
&#xD;
          -  Whose serum calcium levels exceed the upper limit of reference range&#xD;
&#xD;
          -  Who have used any investigational medicinal product and/or participated in any&#xD;
             clinical study within 24 weeks&#xD;
&#xD;
          -  Who have been treated with systemic therapy within 8 weeks&#xD;
&#xD;
          -  Who have been treated with biologics within 12 weeks&#xD;
&#xD;
          -  Who have been treated with topical therapy during the wash-out and lead-in period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>R&amp;D Administration Department</name_title>
    <organization>Maruho Co.,Ltd ãƒ»Kyoto R&amp;D Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

